Background: To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of individual patient-level factors and time by integrating the patient-level safety data from the QVA149 clinical programme with relevant information from the independent indacaterol and glycopyrronium safety databases. Methods: Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of !3 month's duration with at least two of the treatment groups: QVA149 110/50 mg, glycopyrronium 50 mg, indacaterol 150 mg, placebo or tiotropium 18 mg. Overall hazard ratio (HR) was assessed between the active treatments and placebo and in various subgroups related to severity of airways obstruction, inhaled corticosteroid use, cardiovascular risk factors, sex, age and body mass index for death, serious cases of cardio-and cerebrovascular (CCV) events, major adverse * Corresponding author. National Heart and Lung Institute, Imperial College London, London SW3 6LR, UK. Conclusions: There was no increase in the risk for the investigated safety endpoints for the fixed-dose combination QVA149, and it had a comparable safety profile as its monocomponents and tiotropium versus placebo.
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Introduction
Long-acting bronchodilators (b 2 -agonists and/or muscarinic antagonists) are the foundation of the pharmacological management strategy for patients with chronic obstructive pulmonary disease (COPD) at all severity levels of the disease (alternative choice for GOLD group A and first choice for GOLD B-D) [1] . Dual bronchodilation with a long-acting b 2 -agonist (LABA) and long-acting muscarinic antagonist (LAMA) is recommended for patients with a high symptomatic burden and/ or risk of exacerbations, as well as for patients who remain symptomatic on mono-bronchodilator therapy [1, 2] . It provides additional clinical benefits in terms of improving efficacy and has the potential to decrease the rate of side effects compared with increasing the dose of a mono-bronchodilator [1] and avoiding risks such as pneumonia associated with the use of LABA/inhaled corticosteroid (ICS) combinations [3] .
The safety profile of bronchodilators in COPD remains of prime importance [4, 5] . Studies such as Towards a Revolution in COPD Health (TORCH) and Understanding Longterm Impacts on Function with Tiotropium (UPLIFT) have provided the evidence that long-acting bronchodilators at therapeutic doses in stable COPD do not increase risk of the cardio-and cerebrovascular (CCV) mortality or morbidity in patients with COPD [6, 7] .
The efficacy and safety of free-dose combinations of long-acting bronchodilators such as salmeterol with tiotropium, formoterol with tiotropium, indacaterol with tiotropium, and indacaterol with glycopyrronium compared with either one or both monocomponents have been reported in several studies of 6e26 weeks of duration in patients with COPD. In these studies, the free combination showed a similar safety profile compared with their respective monocomponents [8e11]. QVA149 is an inhaled once-daily (o.d.) dual bronchodilator containing a fixeddose combination of the LABA indacaterol maleate and LAMA glycopyrronium bromide which along with its monocomponents, is approved in the European Union, Japan, Canada and other countries for the maintenance treatment of patients with COPD. The efficacy and safety of QVA149 [12e14], indacaterol [15e19] and glycopyrronium [20, 21] versus placebo and active comparators have been demonstrated in their clinical development programmes. In the pivotal Phase III Indacaterol and GlycopyrroNium bromide clInical sTudiEs (IGNITE) clinical trial programme, QVA149 o.d. demonstrated an acceptable safety profile, with adverse events (AEs) and serious AEs (SAEs) being similar to placebo, its monocomponents, tiotropium or salmeterol/ fluticasone combination (SFC) [12e14, 22, 23] .
Here, we report a pooled analysis that was conducted to analyse specific safety events that are of importance in patients with COPD, so as to provide a more comprehensive evaluation of the safety profile of QVA149. The present analysis integrated the patient-level safety data across the QVA149 IGNITE programme with the available relevant information from the indacaterol and glycopyrronium safety databases so that individual components and their fixed dose combination can be examined together along with a standard of care, tiotropium. This analysis investigated the impact of individual patient risk factors and duration of exposure to study medications and provided additional assessments on infrequently occurring safety endpoints.
Methods

Study design and selection
All randomised clinical trials from QVA149, indacaterol and glycopyrronium programmes were reviewed for the purpose of this pooled analysis. The focus of the pooled analysis was to provide information on key safety endpoints for QVA149, and the monocomponents studies were included as a part of its evaluation. The individual study designs of 14 included studies for this pooled analysis are summarised in Supplementary Appendix 1 Table A1 .
This pooled analysis included data from all completed phase III randomised clinical trials of !3 month's duration (study completion date as of September 30, 2012) . For studies involving indacaterol, only patients that received the 150 mg dose were included in the analysis as this corresponds to the equivalent indacaterol dose used in QVA149. In order to match the fine particle dose of indacaterol in both the combination and the 150 mg monotherapy product, the dose of indacaterol in QVA149 is 110 mg and the two doses can be considered clinically equivalent [24] . Further details on dose adjustment are given in Supplementary Appendix 2.
The methods and the main results of the included studies have been previously published or presented in detail. The studies included from the indacaterol programme were: INdacaterol: vs tiotropium to Help Achieve New COPD treatment Excellence (INHANCE) [19, 25] [17] , B1302 [26] , and B2333 [27] ; glycopyrronium programme: GLycopyrronium bromide in COPD airWays clinical study 1(GLOW1) [20] , GLOW2 [21] , and GLOW4 [28] ; and QVA149 IGNITE programme: SHINE [12] , SPARK [13] , ENLIGHTEN [14] , and ARISE [29] . In the INTENSITY [15] study, blinded tiotropium was used as an active comparator while INHANCE [19] , GLOW2 [21] , SHINE [12] , SPARK [13] and ARISE [29] studies had open-label tiotropium as an active comparator. All included studies were approved by institutional review boards and ethics committees at participating centres, and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All the patients provided written informed consent.
Patients/study population
The patients' inclusion and exclusion criteria in this pooled analysis were similar across all studies. The protocols of the included studies allowed patients with stable co-morbid cardiovascular conditions to be screened and included in studies at the discretion and judgment of the investigator.
The studies enrolled men and women aged !40 years with moderate-to-severe COPD (Stage II or III according to the GOLD 2005 and 2008 criteria; post-bronchodilator forced expiratory volume in 1 s [FEV 1 ] of !30% and <80% of the predicted normal; post-bronchodilator FEV 1 to forced vital capacity (FVC) ratio of <0.70 at screening), with the exception of the SPARK study that had patients with severe-to-very severe COPD (Stage IIIeIV according to the GOLD 2008 criteria; post-bronchodilator FEV 1 50% predicted) and a documented exacerbation history in the last year [13] . Patients were current or ex-smokers with a smoking history of !10 pack-years (!20 pack-years in B1302 [26] , INHANCE [19, 25] , INDORSE [16] , INLIGHT1 [18] , and INLIGHT2 [17] ).
Patients with conditions such as ischaemic heart disease, left ventricular failure, history of myocardial infarction (MI) or arrhythmia (excluding chronic stable atrial flutter/fibrillation [AF/F]) were not specifically excluded from the studies, unless these cardiovascular conditions were regarded as to affect the patient's safety, compliance or ability to complete the study as per the investigator's discretion.
In most of the studies, the key exclusion criteria were: a history of the long QT syndrome or a prolonged QTc interval at screening (>450 ms for males and females), a history of asthma or a clinically abnormal electrocardiogram (ECG) that could potentially place patients at risk if enrolled into the study as per the investigator's discretion.
Evaluations and outcome measures
The present analysis focused on infrequently occurring safety endpoints that included the risk of death (all-cause mortality), CCV events, major adverse cardiovascular [26] 12 weeks 0 114 0 0 117 Glycopyrronium GLOW1 [20] 26 weeks 0 0 550 0 267 GLOW2 [21] 52 weeks 0 0 525 267 268 GLOW4 [28] 52 weeks 0 0 123 40 0 QVA149 SHINE [12] 26 weeks 474 476 473 480 232 SPARK [13] 64-76 weeks 729 0 740 737 0 ENLIGHTEN [14] 52 weeks 225 0 0 0 113 ARISE [29] 52 events (MACEs), pneumonia, COPD exacerbations requiring hospitalisation and atrial flutter/fibrillation. MACEs were categorised as non-fatal MI, unstable angina, non-fatal stroke, heart failure requiring hospitalisation and coronary revascularisation. The details of the terms are included in the Supplementary Appendix 2.
The overall hazard ratio (HR) was assessed between placebo and active therapy arms that included o.d. QVA149, indacaterol, glycopyrronium or tiotropium by incorporating the relevant covariates that may have impact on the safety outcome.
In addition, it was assessed whether there was any evidence that the HR of QVA149 or any other drug versus placebo changes over time in various subgroups based on the following baseline factors: severity (moderate [FEV 1 >50% and <80% of the predicted normal] and severe or very severe based on GOLD 2008); ICS use (yes or no); cardiovascular (CV) risk factors (0e2 or !3); sex (male or female); age group (<65 or !65 years) and body mass index (BMI; <30 or !30 kg/m 2 ). CV risk factors were determined based on the following baseline conditions: presence of CCV history/condition at baseline based on the pre-defined Standardised Medical Queries (SMQs) including MI, ischaemic heart disease, cardiac failure, ischaemic and haemorrhagic cerebrovascular conditions, and cardiac arrhythmias; presence of hypertension at baseline; presence of hyperlipidaemia at baseline; presence of history of diabetes mellitus (type II); b CCV condition determined based on the following pre-defined standardised MedDRA queries (SMQs) search criteria: myocardial infarction (20,000,047, narrow), other ischaemic heart disease (20,000,168, narrow), cardiac failure (20,000,004, narrow), ischaemic and haemorrhagic cerebrovascular conditions (20,000,063 and 20,000,064, narrow), and cardiac arrhythmia terms (20,000,050, broad). 
MACEs included non-adjudicated events from the indacaterol and glycopyrronium studies and adjudicated events from the QVA149 programme (performed by an independent adjudication committee). Adjudicated MACEs, when available or treatment-emergent SAEs as reported by investigators or identified using pre-defined search criteria, within 30 days of the last dose, were included in the analysis.
Statistical analysis
All analyses were based on the safety population defined as all randomised patients who received at least one dose of the study medication. The exposure data were collected on electronic case report forms. Serious events of interest were included only if the start date was within 30 days of the last study dose. As studies were completed at various times, AEs were coded with different MedDRA versions. For the pooled analysis database, lower-level term codes were mapped to the latest MedDRA version (version 15.0). Data were analysed using a Cox proportional hazard model, with treatment, study, COPD severity, ICS use and the number of CV risk factors as fixed covariates.
The subgroup analyses of the time to first event were also performed using a Cox regression model with factors for treatment, study, baseline COPD severity (GOLD 2008), baseline ICS use, number of CV risk factors and the subgroup by treatment interaction term. For the subgroups of sex, age and BMI, the model also included the factor for subgroup.
The estimated HRs (active treatment versus placebo) along with its 95% confidence interval (CI) was calculated from the model and was used to interpret the results. For AF/F, only adjudicated data from QVA149 studiesdSHINE [12] , SPARK [13] , ENLIGHTEN [14] , and ARISE [29] and glycopyrronium studiesdGLOW1 [20] , GLOW2 [21] , and GLOW4 [28] were available for use (adjudicated by an independent committee). Non-adjudicated data from indacaterol studies were used in the analysis, as adjudicated data were not available.
The model was based on the assumptions that all patients share an equivalent baseline hazard function over time, and the model accounts for the treatment and the impact of different studies, COPD severity, ICS use status and CV risk factors on the hazard.
Results
Patient characteristics
The analysis included safety data from 11,404 patients, with 1547 receiving QVA149; 2528 receiving indacaterol; 2411 receiving glycopyrronium; 2777 receiving tiotropium; and 2141 receiving placebo (Table 1 ). Baseline patient demographics and other clinical characteristics were comparable across all the treatment groups, with the notable exception that more patients in the QVA149 group versus the other treatment groups had severe or very severe COPD (65.1% versus 39.8%e57.2%), due to the inclusion of data from the SPARK study. There was also a higher percentage of patients who used ICS at baseline (61.3% versus 42.9%e 60.5%) in the QVA149 treatment arm while fewer patients on QVA149 had !2 CV risk factors at study entry (30.7% versus 46.8%e55.6%). The tiotropium group had more Caucasian patients (82.0% versus 68.0%e74.9%) and less Asian patients (13.0% versus 20.7%e28.1%) than the other treatment groups (Table 2 ).
Safety
The mean exposure was highest in the QVA149 group (333.2 days) compared with its monocomponents indacaterol (138.4 days) and glycopyrronium (283.1 days), tiotropium (228.8 days) and placebo (178.6 days), due to the inclusion of the SPARK study that had a treatment duration of 64e76 weeks. A higher proportion of patients in the QVA149 group (83.6%) were treated for more than 6 months compared with the other treatment groups (30.6%e75.7%), with 51.7% of the patients in the QVA149 group being treated for more than 12 months (Supplementary Appendix 3 Table A2 ).
The HRs for QVA149 versus placebo and tiotropium versus placebo showed no significant increase in the overall risk for death, serious CCV events, MACEs, pneumonia or AF/F (Fig. 1) . The overall risk of COPD exacerbation was significantly lower for QVA149 versus placebo (HR: 0.60; 95% CI: 0. There was no significant increase in the risk for QVA149 or tiotropium versus placebo for any of the analysed CV safety endpoints for all subgroups related to severity of COPD (GOLD 2008) , baseline ICS use, CV risk factors, sex, age or BMI (Fig. 1aec) . Overall, the HR values for QVA149 versus placebo were comparable to those observed with tiotropium versus placebo subgroups in a cross-comparison manner.
The risk of COPD exacerbation was significantly lower for QVA149 versus placebo in the subgroups (moderate COPD, baseline ICS use, female, age <65 years, BMI <30 kg/m 2 ). Similar results were seen with those observed with tiotropium versus placebo and glycopyrronium versus placebo (Fig. 1c and Supplementary Appendix 4 Fig. A1c ). However, as mentioned earlier, tiotropium was open label in 5 of 6 studies.
adjudicated events from the indacaterol and glycopyrronium studies and adjudicated events from the QVA149 programme (c) COPD exacerbation requiring hospitalisation and Atrial flutter/fibrillation (AF/F) BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HR, hazard ratio; ICS, inhaled corticosteroid; All AF/F events were adjudicated.
The risk of serious CCV events was significantly lower in patients with baseline ICS use for QVA149 versus placebo (HR: 0.35; 95% CI: 0.14e0.86). The risk of serious CCV events was also shown significantly lower in patients with !3 CV risk factors for tiotropium (HR: 0.45; 95% CI: 0.22e0.96, Fig. 1a ) and glycopyrronium versus placebo (HR: 0.47; 95% CI: 0.23e0.99, Supplementary Appendix 4 Fig. A1a) , with similar risk with QVA149 versus placebo (HR: 0.67; 95% CI: 0.29e1.53, Fig. 1a) .
The HR values in some of the subgroups investigated for all treatments versus placebo had wide 95% CI around the outcomes ( Fig. 1 and Supplementary Appendix 4 Fig. A1) , which is likely due to low number of events and/or low number of patients with in these subgroups or variation in the data. Most importantly, none of the differences in the HRs suggested significantly increased risk.
There was also no significant increase in the overall risk and in the subgroups for death, serious CCV events, MACEs, pneumonia, COPD exacerbations requiring hospitalisation or AF/F for indacaterol versus placebo and glycopyrronium versus placebo except for MACE in patients with BMI !30 kg/m 2 for glycopyrronium versus placebo where HR was in favour of placebo (HR: 3.03; 95%CI: 1.02e8.97) (Supplementary Appendix 4 Fig. A1 ).
Discussion
The current pooled analysis included data from 11,404 patients from 14 randomised clinical trials across multiple safety databases. It was observed that the fixed-dose combination QVA149 indirectly compared with its monocomponents (indacaterol and glycopyrronium), tiotropium and versus treatment with placebo did not increase the risk of death (all-cause mortality), serious cases of cardio-and cerebrovascular (CCV) events, major adverse cardiovascular events (MACEs), pneumonia, COPD exacerbations requiring hospitalisation or atrial flutter/fibrillation (AF/F) events overall and in a diverse range of subgroups.
The technique of pooled analysis of randomised controlled trials, in which data is pooled from trials having at least one intervention in common with another, has been used recently for analysing data, as it allows comparison of multiple interventions that have not been evaluated directly against each other [30] . The analysis of pooled data may also help to identify safety events that might occur at low frequencies in the individual data sets.
The results observed with QVA149 versus placebo in the current analysis did not show any increase in risk for any of the investigated safety points. The results were consistent with the QVA149 cardiac safety data from Phase III studies, and confirmed that no significant cardiovascular safety or mortality concerns were observed in these studies with QVA149 [12, 13, 22] .
CCV diseases have been reported to occur at increased rates in patients with COPD, perhaps because of shared risk factors such as smoking [31] . Rates of incident cardiovascular events are also increased in these patients [32] .
In the current analysis, there was no significant increase in the risk for MACEs and other cardiovascular safety end points (serious CCV and AF/F) with QVA149 versus placebo despite the inclusion of more patients with severe and very severe COPD in the QVA149 group (65.1%). QVA149 also did not increase the risk of death versus placebo, and the results were comparable to those observed with tiotropium versus placebo. The results of the pooled analysis suggests that the risk of cardiovascular events for QVA149 versus placebo was comparable between older patients (age !65 years) and younger patients (age < 65 years); patients with moderate COPD and those with severe COPD; patients with high CV risk (CV risk factor ! 3) and low risk (CV risk factor 0e2); and in obese patients (BMI ! 30 kg/m 2 ) or otherwise (BMI < 30 kg/m 2 ). These data provide some level of assurance of the cardiovascular safety of QVA149 in higher risk patients.
The results observed for tiotropium versus placebo in the current analysis were consistent with those observed previously in the UPLIFT study [7, 33] and other reported metaanalyses of tiotropium 18 mg administered via the HandiHaler â device for the risk of all-cause mortality [34, 35] and major cardiovascular events versus placebo [36] .
Clinically important subgroups of patients based on attributes such as age, sex, co-morbid condition or some combination of these attributes can influence the level of responsiveness to the treatment of COPD. Hence, it is important to analyse the effect of the treatment in the subgroups [37] .There was no significant increase in risk with QVA149, indacaterol or glycopyrronium versus placebo for most of the subgroups related to severity, baseline ICS use, CV risk factors, sex, age or BMI for any of the investigated safety end points. The results were comparable to the tiotropium versus placebo data in a cross-comparison manner.
The results for indacaterol versus placebo were also consistent with those of other reported meta-analysis and pooled studies of indacaterol 150 mg in terms of mortality and exacerbations, and did not show any significant increase in the overall risk for any of the investigated subgroups [38, 39] .
In the current pooled analysis, QVA149 was not associated with an increase in the overall risk of pneumonia compared with placebo (HR: 1.10; 95% CI: 0.54e2.25) and in the subgroup related to baseline ICS use (HR: 1.05; 95% CI: 0.43e2.56). This provides additional evidence that the fixed-dose LABA/LAMA combinations, such as QVA149, could be a useful treatment option for symptomatic patients with COPD, as it demonstrated similar safety profile compared with its monocomponents.
Potential limitations of this pooled analysis include the fact that the trials included in the pooled analysis were not specifically designed and powered to evaluate CV events and patients with high CV risks were excluded from the studies. Real-life long-term safety studies with more patients and longer-term follow-up are required to analyse the safety of drugs in such patients. Events were recorded only during the duration of the studies (until 30 days of last treatment) and vital status follow up was not performed in most of the studies. Further, tiotropium was open-label in all studies included in the pooled analysis, except for IN-TENSITY, where blinded tiotropium was used. Also, the number of GOLD IV (very severe) patients was limited in the analysis (SPARK study only).
However, the strength of the current pooled analysis lies in the fact that the safety data have been pooled from 12 published and 2 reported randomised clinical trials, with more than 11,000 patients with COPD being included in the analysis. The trials included in the analysis had similar inclusion and exclusion criteria, with the exception of the SPARK study, and there was no evidence of clinical or statistical heterogeneity between the trials. Different subgroups based on the severity, baseline ICS use, CV risk factors, sex, age and BMI were explored, which reflect the overall risk factors in a general population of COPD. The statistical analysis was conducted using the Cox proportional hazard model, which incorporated the important covariates such as study, baseline COPD severity, baseline ICS use, number of CV risk factors. Further, the adverse event reporting was complete for all the trials despite some being of shorter duration and extended to 30 days after the last study medication. Adjudicated data were used for the analysis, except for atrial fibrillation data for indacaterol where the non-adjudicated data were included in the analysis.
Conclusions
In this pooled analysis across multiple safety databases that included data from 11,404 patients, the incidence of deaths, serious CCV events, MACEs, pneumonia, exacerbations requiring hospitalisation and atrial flutter/fibrillation was comparable between QVA149 and placebo, with no increase in the overall risk being observed for any of the investigated safety endpoints for any of the drugs versus placebo.
There was no increase in infrequent AEs versus placebo for the fixed-dose combination QVA149, and additionally its safety profile was comparable to its monocomponents (indacaterol and glycopyrronium) and tiotropium. These data provide further reassurance that the use of dual bronchodilation may be of clinical benefit to patients with COPD, without a safety penalty.
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